PD-L1 anticorps (AA 39-191)

N° du produit ABIN6939569

Détail du produit anti-PD-L1 anticorps

Antigène: PD-L1 (CD274 (PD-L1))

Épitope: AA 39-191

Reactivité: Humain, Souris

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp PD-L1 est non-conjugé

Application: Western Blotting (WB), ELISA, Coating (Coat)

Purification: Purified by Protein A/G

Immunogène: Recombinant fragment of human CD274 protein (around aa39-191) (exact sequence is proprietary)

Clone: PDL1-2744

Isotype: IgG1 kappa

Information d'application

Indications d'application:

Positive Control: Jurkat, HEK293 or HepG2 cells. Lung SqCC, Cervical or Breast Carcinoma.

Known Application: ELISA (For coating, order antibody without BSA),Western Blot (1-2 μg/mL),Optimal dilution for a specific application should be determined.

Restrictions: For Research Use only

Stockage

Concentration: 200 μg/mL

Buffer: 10 mM PBS with0.05 % BSA & 0.05 % azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-80 °C

Stockage commentaire: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Date de péremption: 24 months

Détails sur PD-L1

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: CD274 (PD-L1 Produits)

Synonymes: anticorps B7-H, anticorps B7H1, anticorps PD-L1, anticorps PDCD1L1, anticorps PDCD1LG1, anticorps PDL1, anticorps A530045L16Rik, anticorps B7h1, anticorps Pdcd1l1, anticorps Pdcd1lg1, anticorps Pdl1, anticorps RGD1566211, anticorps CD274 molecule, anticorps CD274 antigen, anticorps programmed cell death 1 ligand 2, anticorps CD274, anticorps Cd274, anticorps PDCD1LG2

Sujet: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20 % and 15 % identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.

Poids moléculaire: 37-50kDa

ID gène: 29126

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints